Last edition
News about "Marketing Authorisation Revocation"
EMA Panel Recommends Revoking EU Authorisation for Tavneos Over Data Integrity Concerns
CHMP concludes pivotal clinical trial data cannot reliably demonstrate the drug’s efficacy, advises discontinuation for new patients and enhances liver monitoring for existing users.<br />
Marketing Authorisation Revocation | 29/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members